Earnings Feed
Start Free
First Tracks Biotherapeutics, Inc.·4

Apr 22, 4:05 PM ET

Ware J. Anthony 4

4 · First Tracks Biotherapeutics, Inc. · Filed Apr 22, 2026

Research Summary

AI-generated summary of this filing

Updated

First Tracks (TRAX) Director Ware J. Anthony Receives Awards

What Happened

  • Director Ware J. Anthony was granted multiple equity awards on April 20, 2026 in connection with First Tracks Biotherapeutics’ spin-off from AnaptysBio. The grants total 141,615 shares (reported as derivative awards) and were reported at an acquisition price of $0. These awards include outright common stock from the spin-off, adjusted stock options, and restricted stock units (RSUs).

Key Details

  • Transaction date: April 20, 2026. Form 4 filed April 22, 2026 (timely within the usual two-business-day reporting window).
  • Total shares/awards reported: 141,615 shares acquired via awards/grants. Reported price: $0 (no cash paid on grant).
  • Transaction code: A (award/grant); reported as derivative securities (options/RSUs) in the filing.
  • Shares owned after transaction: Not specified in the provided extract of the Form 4.
  • Important footnotes from the filing:
    • F1: Some shares are common stock received in the spin-off from AnaptysBio.
    • F2–F4: Certain awards are adjustments of pre-existing AnaptysBio stock options into First Tracks options; some options are fully vested (F3) and some vest monthly (1/12 per month beginning Feb 6, 2026) (F4).
    • F5–F8: Some awards are RSUs (each convertible to one share on settlement). RSUs were adjusted from AnaptysBio RSUs (F6) and have vesting dates tied to the issuer’s 2026 or 2027 annual meetings (F7, F8).
  • No indication in the filing that shares were sold immediately (no cashless exercise or open-market sale reported).

Context

  • These are grant/adjustment transactions tied to a corporate separation (spin-off). That means several pre-existing AnaptysBio awards were split/adjusted so that the holder now has separate awards for First Tracks and for AnaptysBio.
  • Because most items are options/RSUs and were granted at $0, there was no cash purchase or sale — these are not immediate buy/sell signals. Vesting schedules and settlement conditions will determine when shares become transferable or taxable.

Insider Transaction Report

Form 4
Period: 2026-04-20
First Tracks Biotherapeutics, Inc.TRAX
Ware J. Anthony
Director
Transactions
  • Award

    Stock Option (right to buy)

    [F2][F3]
    2026-04-20+28,571→ 28,571 total
    Exercise: $5.74Exp: 2027-08-21→ Common Stock (28,571 underlying)
  • Award

    Stock Option (right to buy)

    [F2][F3]
    2026-04-20+10,694→ 10,694 total
    Exercise: $5.74Exp: 2027-08-21→ Common Stock (10,694 underlying)
  • Award

    Stock Option (right to buy)

    [F2][F3]
    2026-04-20+6,000→ 6,000 total
    Exercise: $28.03Exp: 2028-02-01→ Common Stock (6,000 underlying)
  • Award

    Stock Option (right to buy)

    [F2][F3]
    2026-04-20+6,000→ 6,000 total
    Exercise: $18.43Exp: 2029-02-07→ Common Stock (6,000 underlying)
  • Award

    Stock Option (right to buy)

    [F2][F3]
    2026-04-20+11,000→ 11,000 total
    Exercise: $4.43Exp: 2030-02-11→ Common Stock (11,000 underlying)
  • Award

    Stock Option (right to buy)

    [F2][F3]
    2026-04-20+11,000→ 11,000 total
    Exercise: $7.95Exp: 2031-02-09→ Common Stock (11,000 underlying)
  • Award

    Stock Option (right to buy)

    [F2][F3]
    2026-04-20+9,200→ 9,200 total
    Exercise: $8.14Exp: 2032-02-09→ Common Stock (9,200 underlying)
  • Award

    Stock Option (right to buy)

    [F2][F3]
    2026-04-20+10,600→ 10,600 total
    Exercise: $6.22Exp: 2033-01-05→ Common Stock (10,600 underlying)
  • Award

    Stock Option (right to buy)

    [F2][F3]
    2026-04-20+16,510→ 16,510 total
    Exercise: $5.67Exp: 2034-01-02→ Common Stock (16,510 underlying)
  • Award

    Stock Option (right to buy)

    [F2][F3]
    2026-04-20+16,510→ 16,510 total
    Exercise: $3.97Exp: 2035-01-06→ Common Stock (16,510 underlying)
  • Award

    Stock Option (right to buy)

    [F2][F4]
    2026-04-20+5,500→ 5,500 total
    Exercise: $11.75Exp: 2036-01-06→ Common Stock (5,500 underlying)
  • Award

    Restricted Stock Unit

    [F5][F6][F7]
    2026-04-20+6,030→ 6,030 total
    → Common Stock (6,030 underlying)
  • Award

    Restricted Stock Unit

    [F5][F6][F8]
    2026-04-20+4,000→ 4,000 total
    → Common Stock (4,000 underlying)
Holdings

  • Common Stock

    [F1]
    9,630
Footnotes (8)
  • [F1]Consists of shares of common stock received in connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") from AnaptysBio, Inc. ("AnaptysBio").
  • [F2]Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.
  • [F3]The stock option is fully vested and exercisable.
  • [F4]The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  • [F5]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  • [F6]Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.
  • [F7]The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  • [F8]The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Signature
/s/ Ajim Tamboli, Attorney-in-Fact|2026-04-22

Documents

2 files